Traws Pharma
TRAW
18 hedge funds and large institutions have $2.41M invested in Traws Pharma in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 4 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
29% more capital invested
Capital invested by funds: $1.87M → $2.41M (+$543K)
4.24% less ownership
Funds ownership: 22.71% → 18.47% (-4.2%)
5% less funds holding
Funds holding: 19 → 18 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$121K |
| 2 |
HF
HRT Financial
New York
|
+$20.5K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$17.5K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$12.6K |
| 5 |
Two Sigma Investments
New York
|
+$9.71K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$77.9K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$25.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.89K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.04K |
| 5 |
Raymond James Financial
St Petersburg,
Florida
|
-$151 |
TRAW Hedge Fund Activity: Q3 2025 in Review
18 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q3 2025, worth a combined $2.41M — up 29% from $1.87M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of TRAW and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $121K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $77.9K sold.
- 18 institutional investors held Traws Pharma (TRAW) as of Q3 2025, down from 19 in Q2 2025.
- Funds reported $2.41M of Traws Pharma stock for Q3 2025, up 29% quarter-over-quarter.
- 3 funds opened new Traws Pharma positions in Q3 2025 and 4 closed out, a net change of -1 holder.
- The largest Traws Pharma buyer in Q3 2025 was Vanguard Group, an estimated $121K added.
- The largest Traws Pharma seller in Q3 2025 was Alyeska Investment Group, an estimated $77.9K sold.
Based on aggregated 13F filings for Q3 2025.